🔬 I’ll be at #ASCO25 to discuss the differential genomic landscape of ER-low vs ER+ and ER- m+ #breastcancer. Join the conversation at Poster Board 50 on 6/2/25, 9:00 AM–12:00 PM! #bcsm @danafarber.bsky.social @danafarbernews.bsky.social @ascocancer.bsky.social www.asco.org/abstracts-pr...

Try and play with it. All the feedback will be welcomed by @ascocancer.bsky.social and @newsfromgoogle.bsky.social ! ASCO Guidelines Assistant is available to anyone with an ASCO account until June 8, 2025. After this date, use of this tool is an exclusive benefit for ASCO members.

American Society of Clinical Oncology@ascocancer.bsky.social · last yr.

🚨New from ASCO: The ASCO Guidelines Assistant, a new generative AI tool developed in collaboration with Google Cloud, more quickly connects ASCO members with timely and trustworthy information. #ASCO25 Learn more: brnw.ch/21wSP18

🚨NEW @ascocancer.bsky.social #EduBook chapter: @hoperugo.bsky.social, @stolaney1.bsky.social & I unpack the most debated trial design issues in m+ #BreastCancer —suboptimal control arms, crossover challenges, post-progression tx, non-inferiority margins, patient selection. ➡️ shorturl.at/nZWdI #bcsm

Decoding Clinical Trials in Metastatic Breast Cancer: Practical Insights for Optimal Therapy Sequencing

The art of sequencing therapy in the management of breast cancer is a multifaceted challenge that demands the careful integration of clinical trial data, real-world evidence, and individualized patien...

shorturl.at

In medio stat virtus

Emil Lou, MD, PhD, FACP, FASCO@cancerassassin1.bsky.social · last yr.

Right in time for #AACR25: two insightful commentaries this week on the topics of critical thinking and critiquing science and #clinicaltrials results. It can be done with respect, and we need that type of objectivity more than ever jamanetwork.com/journals/jam... www.ejcancer.com/article/S095...

Scientific publishers are under siege by distant buyers, flipping journals to #OpenAccess and raising APCs. @Nature article explains the game: “Invasion of the ‘journal snatchers’: the firms that buy science publications and turn them rogue” www.nature.com/articles/d41...

Invasion of the ‘journal snatchers’: the firms that buy science publications and turn them rogue

Study finds dozens of journals that have hiked their fees and started churning out papers after being acquired by small, recently formed companies.

nature.com

“Education is one of the few forces powerful enough to break the cycle of #poverty. It gives children born into hardship the tools to rewrite their story—and shape a future of their own making.”

Don't miss this newly published review discussing recent advances in immune checkpoint inhibitors for #TripleNegativeBreastCancer. 🔓 pubmed.ncbi.nlm.nih.gov/40196378/ @ccortimd.bsky.social @stolaney1.bsky.social #TNBC #BreastCancer

www.sciencedirect.com/science/arti... If your business model is still selling algorithms, please stop. The accuracy of models is limited in time and space. The pursuit of generalizability is misguided. AI should be local, iterative, reflective and reflexive.

Global disparities in artificial intelligence-based mammogram interpretation for breast cancer: A scientometric analysis of representation, trends, and equity

Breast cancer (BC) is the most frequently diagnosed cancer and the leading cause of cancer death among women worldwide. Artificial intelligence (AI) s…

sciencedirect.com

"Global disparities in artificial intelligence-based mammogram interpretation for breast cancer: A scientometric analysis of representation, trends, and equity" shorturl.at/Q7xFo .

From #immunotherapy (IO) failures to new strategies & biotech innovations in metastatic TNBC, to IO timing, chemo backbones, & novel approaches in the early stage. All this & more in our latest review on immune checkpoint inhibitors in #TNBC. shorturl.at/izpbe @dfcibreastonc.bsky.social

Great to stop by #USCAP25 this afternoon to support our team’s work using #MachineLearning to characterize the tumor microenvironment in post-surgical #TNBC specimens after neoadjuvant chemo. @dfcibreastonc.bsky.social @uscap.org

AI-generated content floods literature with poor-quality publications, casts doubt on metrics, @science.org and Retraction Watch investigation finds. www.science.org/content/arti...

Shoddy commentaries—a quick and dirty route to higher impact numbers—are on the rise

AI-generated content floods literature with poor-quality publications, casts doubt on metrics, Science and Retraction Watch investigation finds

science.org

Merry Christmas to all. Health truly is our most precious gift - It’s not just a cliché. For some, this season means remembering a loved one, facing a tough diagnosis, starting a new treatment, or getting difficult scan results. My heart is with you. ❤️

🚨 NY Gov. Kathy Hochul signs bill mandating private insurers cover scalp cooling systems starting Jan 1, 2026. 👏 First state to do so—hopefully paving the way for universal access. #CancerCare #HealthEquity #bcsm shorturl.at/AXNdm

Breakthrough law offers cancer patients in New York relief for 'scalp-cooling therapy'

New York has become the first state in the country to require insurance coverage for what's called "scalp-cooling therapy," which can reduce hair loss for chemo patients.

shorturl.at

Great work showing half of patients with metastatic relapse after adjuvant abemaciclib have loss of estrogen expression. Biopsy remains critical. #sabcs24 @oncbrothers.bsky.social

Chiara Corti, MD@ccortimd.bsky.social · 2y ago

Thank you all for stepping by and chatting with me yesterday. Thanks to @dfcibreastonc.bsky.social , my mentor @stolaney1.bsky.social , and all the co-authors for this great opportunity 😊 #SABCS2024 @sabcs.bsky.social

Post-hoc TAILORx analysis: In HR+/HER2-, LN- breast cancer w/ RS ≥31, anthracycline (T-AC) improved 5-year DRFI (96% vs 91%, aHR 0.32, p=0.009) and DRFS vs TC. Benefit strongest in tumors >2cm, increasing with RS Results are alligned w/ other MammaPrint High 2 results @oncoalert.bsky.social

Join us in Row 10 to see our poster on outcomes in HER2+ & TNBC pts treated with neoadjuvant tx! Key findings: ✅ pCR linked to better outcomes ✅ 3-yr RFS/OS varied by cT, cN, & subtype at dx ✅ In RD pts, cT, cN, & subtype stayed prognostic, but not in pCR pts (few events) #SABCS24 #bcsm

Thank you all for stepping by and chatting with me yesterday. Thanks to @dfcibreastonc.bsky.social , my mentor @stolaney1.bsky.social , and all the co-authors for this great opportunity 😊 #SABCS2024 @sabcs.bsky.social

Don’t miss #SABCS24 Clinical Controversies Session on: Omission of Axillary Staging in ER-Positive #BreastCancer - Implications on Adjuvant Therapies, where Dr. Elizabeth Mittendorf will discuss the current data.

Please join us for the poster session today at 12.30PM! Our work on patients who experienced recurrence on adjuvant abemaciclib is in Row 9, right in front of the exhibitors. We look forward to chatting with you! @sabcs.bsky.social @dfcibreastonc.bsky.social

Meet Chiara Corti, MD(@ccortimd.bsky.social)! She came to Dana-Farber from IEO and the Università degli Studi di Milano. Now a #DFCIAdvancedFellow her research focuses on optimizing #BreastCancer treatment via tumor & microenvironment profiling and leveraging AI to streamline clinical operations.

Biomarker analyses of KN-522 shows most markers (T-cell GEP, HRD, HER2 signaling, PTEN, TNBC subtype) were prognostic but not predictive High TMB showed a signal for pembro benefit, but only in 8% of pts Predictive biomarkers for ICI in early TNBC are urgently needed! @oncoalert.bsky.social

Don’t miss tomorrow’s poster session, with a stellar team! Honored to present with @dfcibreastonc.bsky.social #SABCS2024 @sabcs.bsky.social

Dr. Dos Santos presents data around how the breast is changed during pregnancy...and persists (not just during pregnancy)! 🤰 May explain why parity and age impacts breast cancer risk 📊. Early pregnancy ⬇️ breast cancer risk by 30-40% #SABCS24 @sabcs.bsky.social @oncoalert.bsky.social #bcsm

Hello, #MedSky community! We’re excited to begin our Bluesky journey. Here is a sampling of the trusted, influential, and essential information you can expect when you follow us:

Finally also the amazing @dfcibreastonc.bsky.social group has joined @bsky.app ! Follow this account 👆🏻 for the latest news regarding #breastcancer meetings, clinical trial related info, new research coming out and much more !

We are looking forward to this year's San Antonio Breast Cancer Symposium which starts on December 10. Take a look at the full program for this important meeting featuring the latest research on breast cancer. sabcs.org/FullProgram #SABCS24 #breastcancer

Thrilled to see this labor of love finally out! Many thanks to the amazing and incredibly patient @myESMO publishing team for their support in bringing together diverse perspectives throughout the drafting, editing, and proofreading process. #bcsm #ESMO oncologypro.esmo.org/education-li...

One of the reasons why epistemic diversity is key to good teams and collaborations

Itai Yanai@itaiyanai.bsky.social · 2y ago

Have you experienced "Expert's Dilemma"? The more specialized you become, the less open you are to creative solutions from other fields. But the more you explore other fields, the more you risk losing credibility in your home field. genomebiology.biomedcentral.com/articles/10....

It’s the International Day to End Violence against Women and Girls! 1 in 3 girls and women around the world experience physical and/or sexual violence by: A husband A boyfriend An intimate partner A lover A parent A relative A colleague A boss A stranger bit.ly/3gy8pfq #NoExcuse